Last reviewed · How we verify
Sulbactam Sodium/Ampicillin Sodium
Sulbactam inhibits bacterial beta-lactamases while ampicillin inhibits bacterial cell wall synthesis, together providing broad-spectrum bactericidal activity against beta-lactamase-producing organisms.
Sulbactam inhibits bacterial beta-lactamases while ampicillin inhibits bacterial cell wall synthesis, together providing broad-spectrum bactericidal activity against beta-lactamase-producing organisms. Used for Bacterial infections caused by beta-lactamase-producing organisms (skin and soft tissue infections, intra-abdominal infections, gynecological infections).
At a glance
| Generic name | Sulbactam Sodium/Ampicillin Sodium |
|---|---|
| Also known as | UNASYN-S |
| Sponsor | Pfizer |
| Drug class | Beta-lactam antibiotic with beta-lactamase inhibitor |
| Target | Bacterial penicillin-binding proteins; bacterial beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Ampicillin is a beta-lactam antibiotic that binds to penicillin-binding proteins and disrupts bacterial cell wall synthesis. Sulbactam is a beta-lactamase inhibitor that protects ampicillin from degradation by bacterial beta-lactamases, extending the spectrum of activity to include beta-lactamase-producing gram-positive and gram-negative bacteria.
Approved indications
- Bacterial infections caused by beta-lactamase-producing organisms (skin and soft tissue infections, intra-abdominal infections, gynecological infections)
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Allergic reactions
Key clinical trials
- Antibiotic Prophylaxis in Laparoscopic Cholecystectomy (PHASE4)
- Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection (PHASE4)
- Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration -
- Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients (PHASE4)
- The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulbactam Sodium/Ampicillin Sodium CI brief — competitive landscape report
- Sulbactam Sodium/Ampicillin Sodium updates RSS · CI watch RSS
- Pfizer portfolio CI